Nonvitamin K antagonist oral anticoagulants (NOACs) have been proposed as an
alternative to vitamin K antagonists in atrial fibrillation (AF) patients but the comparative …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been proposed as
an alternative to vitamin K antagonists (VKA) for atrial fibrillation (AF) patients. Some studies …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Background We evaluated the dose-dependent efficacy, safety, and all-cause mortality of
non-vitamin K antagonist oral anticoagulants (NOACs) in “atrial fibrillation (AF) patients who …

Objectives. We conducted a systematic review and network meta-analysis of randomized
controlled trials (RCTs) including the comparison of non-vitamin K antagonist oral …

Aims Randomized trials showed non-inferior or superior results of the non-vitamin-K-
antagonist oral anticoagulants (NOACs) compared with warfarin. The aim of this study was …

Background The non-vitamin K antagonist oral anticoagulants (NOACs) overcame some
limitations of vitamin K antagonists (VKAs), and are at least as effective in stroke prevention …

Background Comparative data of non‐vitamin K antagonist oral anticoagulants (NOAC) are
lacking in patients with atrial fibrillation (AF). Objective We compared effectiveness and …

Summary Background and Objectives Benefits and/or harms (including costs) of non‐
vitamin K oral anticoagulants (NOAC s) versus warfarin therapy need appreciation in relative …

Background—Novel oral anticoagulants (NOACs) have been proposed as alternatives to
vitamin K antagonists for the prevention of stroke and systemic embolism in patients with …